CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Call for Patient Input and Clinical Experts: Cabotegravir/rilpivirine and Cabotegravir sodium

Published on: July 19, 2019
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

cabotegravir/rilpivirine

Brand name TBC
Generic name cabotegravir/rilpivirine
Manufacturer ViiV Healthcare ULC
Indication(s) HIV-1 infection
Project Number SR0628-000
Call for patient input 2019-07-19
Patient input deadline 2019-09-10
Submit patient input Submit
Register as Clinical Expert Register

cabotegravir sodium

Brand name TBC
Generic name cabotegravir sodium
Manufacturer ViiV Healthcare ULC
Indication(s) HIV-1 infection
Project Number SR0628-001
Call for patient input 2019-07-19
Patient input deadline 2019-09-10
Submit patient input Submit
Register as Clinical Expert Register